SecBot SecBot
SC 13G/A ·Filed Nov 9, 2026

REPL

Replimune Group, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed1d 4h ago SEC0000886982-26-000560
Passive stake amendment
Actionable Insight • Neutral

Goldman Sachs' passive 3.3% stake is routine for a large financial institution and does not signal any change in investment thesis. Monitor future 13G amendments for any material increase above 5% or conversion to 13D, which would indicate activist intent.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$22.26
T+0 close · Nov 9, 2026 · via day close
Latest settled
+4.58%
T+1 · $23.28
vs SPY
+4.95%
α at T+1
Next horizon
T+5
in 6d
  1. T+0 · Nov 9 $22.26entry
  2. T+1 · 12h ago +4.58%α +4.95% · $23.28
  3. T+5 · in 6d Pending
  4. T+20 · in 28d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Goldman Sachs filed an amendment to its Schedule 13G for Replimune Group, disclosing beneficial ownership of 3,115,243 shares (3.3% of common stock) as of September 30, 2026. The filing is a routine passive stake update with no change in investment intent; the stake remains below 5% and consistent with prior filings.

Key Financial Metrics

Stake
3.3%
Investor
Goldman Sachs Group Inc

Key Facts

  • Goldman Sachs reports beneficial ownership of 3,115,243 shares of Replimune common stock
  • Stake represents 3.3% of shares outstanding as of September 30, 2026
  • Filing is an amendment to Schedule 13G, indicating passive investment intent
  • Goldman Sachs certifies shares were acquired and held in ordinary course of business, not to influence control

Financial Impact

3.3% stake valued at approximately $62.7M based on $1.9B market cap

Risk Factors

  • No material risks identified from this routine passive stake filing

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
87% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
SC 13G/A Filing (Primary)0000886982-26-000560
Document: 0000886982-26-000560-index-headers.html0000886982-26-000560
Document: 0000886982-26-000560-index.html0000886982-26-000560
Document: 0000886982-26-000560.txt0000886982-26-000560

Track record

31 reports on REPL

Performance horizon

9 of 13 bullish or bearish reports moved the stock their way by T+60. Best: +188.35% at T+20 after the Jul 30, 2026 report. 13 of 14 went positive at some point.

Filters
  1. Nov 10, 2026today Insider Cluster Neutral 2/10 Entry $23.47 Now $23.28 −0.81% settles Feb 9
  2. Nov 10, 2026today SC 13G Neutral 3/10 Entry $22.00 Now $23.28 +5.82% settles Feb 8
  3. Nov 9, 20261d ago 144 Neutral 2/10 Entry $22.51 Now $23.28 +3.42% settles Feb 8
  4. Nov 9, 20261d ago SC 13G/A Neutral 2/10 Viewing Entry $22.26 Now $23.28 +4.58% settles Feb 5
  5. Nov 6, 20264d ago 10-Q/A Neutral 3/10 Entry $22.26 Now $23.28 +4.58% settles Feb 5
  6. Nov 4, 20266d ago Institutional Cluster Bearish 4/10 Entry $20.69 Now $23.28 −12.52% settles Feb 2
  7. Nov 3, 20267d ago 144 Neutral 2/10 Entry $20.69 Now $23.28 +12.52% settles Feb 2
  8. Nov 2, 20268d ago 144 Neutral 2/10 Entry $20.65 Now $23.28 +12.74% settles Feb 1
  9. Oct 30, 202611d ago 144 Neutral 2/10 Entry $19.49 Now $23.28 +19.45% settles Jan 29
  10. Oct 28, 202613d ago 144 Neutral 2/10 Entry $17.39 Now $23.28 +33.87% settles Jan 27
Showing 10 of 31

US Market Status

Market Closed · Opens Wed (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026